BCRX FY 2020 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$18M-63.5% YoY

Gross Profit

$16M90.6% margin

Operating Income

-$175M-981.1% margin

Net Income

-$183M-1026.4% margin

EPS (Diluted)

$-1.09

Cash Flow

Operating Cash Flow

-$137M

Free Cash Flow

-$138M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$335M

Total Liabilities

$354M

Stockholders' Equity

-$19M

Cash & Equivalents

$272M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$18M	$49M	-63.5%
Gross Profit	$16M	$45M	-63.9%
Operating Income	-$175M	-$99M	-75.7%
Net Income	-$183M	-$109M	-67.9%